Profiles of Lung Adenocarcinoma With Multiple Ground-Glass Opacities and the Fate of Residual Lesions.
Shimada Y, Maehara S, Kudo Y, Masuno R, Yamada T, Hagiwara M, Kakihana M, Kajiwara N, Ohira T, Ikeda N.
Ann Thorac Surg. 2020 Jun;109(6):1722-1730. doi: 10.1016/j.athoracsur.2019.12.062. Epub 2020 Feb 10.
PMID:32057816
The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.
Cheng B, Li C, Li J, Gong L, Liang P, Chen Y, Zhan S, Xiong S, Zhong R, Liang H, Feng Y, Wang R, Wang H, Zheng H, Liu J, Zhou C, Shao W, Qiu Y, Sun J, Xie Z, Liang Z, Yang C, Cai X, Su C, Wang W, He J, Liang W.
Signal Transduct Target Ther. 2024 Apr 19;9(1):93. doi: 10.1038/s41392-024-01799-z.
PMID:38637495
Prognostic Classification of Multiple Primary Lung Cancers Based on a Ground-Glass Opacity Component.
Hattori A, Takamochi K, Oh S, Suzuki K.
Ann Thorac Surg. 2020 Feb;109(2):420-427. doi: 10.1016/j.athoracsur.2019.09.008. Epub 2019 Oct 5.
PMID:31593656
Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma.